Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy remains poor. The aim of this systematic revie...
Main Authors: | Enrico Capuzzi, Alice Caldiroli, Martina Capellazzi, Ilaria Tagliabue, Matteo Marcatili, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/17/9338 |
Similar Items
-
Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
by: Alice Caldiroli, et al.
Published: (2021-12-01) -
Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
by: Matteo Marcatili, et al.
Published: (2022-09-01) -
The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01) -
Intranasal esketamine use in bipolar disorder: A case report
by: Courtney Skriptshak, PharmD, et al.
Published: (2021-07-01) -
Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)